Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 15/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | POLG | P54098 | 2/20 | 0.70 |
| ▸ | POLA1 | P09884 | 1/20 | 0.70 |
| ▸ | PNP | P00491 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9054447 | 0.89 | HPRT1 (0.90) | HPRT1PNP | |
| SCHEMBL15078255 | 0.88 | POLB (0.72) | HPRT1POLBPOLGPOLA1PNP | |
| SCHEMBL15078166 | 0.88 | POLB (0.72) | HPRT1POLBPOLGPOLA1PNP | |
| SCHEMBL15078155 | 0.88 | POLB (0.72) | HPRT1POLBPOLGPOLA1PNP | |
| Ammonia Solution, Strong SCHEMBL7750989 | 0.87 | POLG (0.66) | HPRT1POLBPOLGPOLA1PNP | |
| SCHEMBL15630235 | 0.83 | PNP (0.69) | HPRT1POLBPOLGPOLA1PNP | |
| SCHEMBL30760008 | 0.83 | POLB (1.00) | HPRT1POLBPOLGPOLA1PNP | |
| SCHEMBL15630242 | 0.83 | POLG (0.70) | HPRT1POLBPOLGPOLA1PNP | |
| SCHEMBL15078152 | 0.82 | POLB (0.68) | HPRT1POLBPOLGPOLA1PNP | |
| SCHEMBL15630219 | 0.81 | PNP (0.64) | HPRT1POLBPOLGPOLA1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3578563-B1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2019-04-11 | — | — | US | disclosed |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2017-08-17 | — | — | US | disclosed |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2017-08-17 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593137-B2 | Guanine analogs as telomerase substrates and telomere length affectors | GERON CORPORATION (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2015-10-22 | — | — | US | disclosed |
| WO-2013095684-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | GERON CORPORATION (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562926-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885POLG 158/4885 |
| US-20170233419-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885POLG 158/4885 |
| US-10035814-B2 | Guanine analogs as telomerase substrates and telomere length affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885POLG 158/4885 |
| US-20200283461-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885POLG 158/4885 |
| US-20150299232-A1 | GUANINE ANALOGS AS TELOMERASE SUBSTRATES AND TELOMERE LENGTH AFFECTORS | TERT, POT1, TERF2 | HPRT1 41/4885POLB 228/4885POLG 157/4885 |
| US-20190106447-A1 | Guanine Analogs as Telomerase Substrates and Telomere Length Affectors | TERT, POT1, TERF2 | HPRT1 38/4885POLB 219/4885POLG 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.